All AbMole products are for research use only, cannot be used for human consumption.
Piclamilast (RP 73401) is a selective PDE4 inhibitor with IC50 of 1 nM at PDE4 from human neutrophils. Inhibition of PDE4 blocks hydrolysis of cAMP thereby increasing levels of cAMP within cells. cAMP suppresses the activity of immune and inflammatory cells. Piclamilast also inhibits LTB4 synthesis in human neutrophils with IC50 of 2 nM. PDE4 inhibitor Piclamilast (RP 73401) displays >19,000-fold selectivity over other PDE isoenzymes. It is comparable to other PDE4 inhibitors for its anti-inflammatory effects. Piclamilast pre-treatment significantly inhibited the changes in 23 genes via mechanisms involving AP-1 activation and c-Jun phosphorylation at Ser63.
Molecular Weight | 381.25 |
Formula | C18H18Cl2N2O3 |
CAS Number | 144035-83-6 |
Solubility (25°C) | DMSO |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related PDE Products |
---|
MR-L2
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM. |
MMPX
MMPX is a potent PDE1 inhibitor. |
T-0156
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. |
TPN171
TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH). |
Mesopram
Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.